PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
9.15%
Revenue growth above 1.5x 3088.T's 4.75%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
5.86%
Gross profit growth above 1.5x 3088.T's 1.28%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
12.81%
EBIT growth below 50% of 3088.T's 32.67%. Michael Burry would suspect deeper competitive or cost structure issues.
12.93%
Operating income growth at 50-75% of 3088.T's 25.38%. Martin Whitman would doubt the firm’s ability to compete efficiently.
-13.39%
Negative net income growth while 3088.T stands at 44.79%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-13.40%
Negative EPS growth while 3088.T is at 45.41%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-13.40%
Negative diluted EPS growth while 3088.T is at 45.36%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend reduction while 3088.T stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-2.38%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-2.38%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
157.75%
10Y revenue/share CAGR 1.25-1.5x 3088.T's 109.33%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
57.39%
5Y revenue/share CAGR at 75-90% of 3088.T's 71.27%. Bill Ackman would encourage strategies to match competitor’s pace.
27.75%
3Y revenue/share CAGR under 50% of 3088.T's 88.12%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
108.53%
Below 50% of 3088.T's 289.28%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
33.23%
Below 50% of 3088.T's 80.19%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-13.11%
Negative 3Y CAGR while 3088.T is 208.73%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
353.50%
10Y equity/share CAGR 1.25-1.5x 3088.T's 252.96%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
90.72%
5Y equity/share CAGR at 50-75% of 3088.T's 132.93%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
41.66%
Below 50% of 3088.T's 111.33%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.07%
Our AR growth while 3088.T is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
3.03%
Inventory growth well above 3088.T's 3.35%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
3.36%
Asset growth above 1.5x 3088.T's 0.49%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
2.00%
Similar to 3088.T's 2.05%. Walter Schloss finds parallel capital usage or profit distribution strategies.
-33.66%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
83.99%
We expand SG&A while 3088.T cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.